(Axios) – The Food and Drug Administration is slated to decide Thursday whether to approve the first new schizophrenia drug in at least three decades. Why it matters: The complex condition is currently treated with antipsychotics that carry safety risks like metabolic disorders, cause weight gain and often cause people to stop taking their medications. (Read More)